radio3D · Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2027-01-01 → 2030-12-31
- EU contribution
- €4,366,500
- Participants
- 21
- Scheme
- HORIZON-TMA-MSCA-DN
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Project objective
Radiopharmaceuticals have become essential for advancing cancer treatment. The radio3D project aims to innovate this field by combining radiotherapy with nanomaterials and 3D disease models. This approach seeks to enhance therapeutic strategies while reducing reliance on animal testing for cancer research. The radio3D project aims to enhance cancer therapy efficacy and safety by employing clinically approved nanomaterials and radioisotopes for imaging and treatment of glioblastoma and pancreatic cancer. Advanced 3D tumour models, such as organoids and bioprinted structures, will be utilised to mimic the tumour microenvironment, enabling efficient drug evaluation, investigation of tumour-stroma interactions, and promotion of personalised medicine while minimising animal testing. The initiative comprises four interdisciplinary work packages, each focusing on training, research, dissemination, and management. This structure promotes cooperation amongst various professionals, including chemists, physicists, biologists, physicians, and entrepreneurs. radio3D brings together 21 groups from academia, industry, and hospitals to elevate cancer treatment research, innovation, and ethical standards. Through the interdisciplinary scientific and intersectoral approach and an extensive and targeted training program radio3D is dedicated to cultivating a new generation of interdisciplinary scientists skilled in nanotechnology, radiolabelling, biomedical imaging, and advanced tumour modelling. By harnessing the synergistic potential of nanomaterials and radiopharmaceuticals, while significantly reducing animal testing, radio3D will advance the field by introducing innovative chemistries and alternative methods for understanding cancer biology to establish a groundbreaking benchmark in nanomedical research, transforming the future of oncology and improving therapeutic outcomes.
Original text from CORDIS.
Participants
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS · MadridCoordinatorSpain
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianSpain
- ASOCIACION INSTITUTO DE INVESTIGACION SANITARIA BIOGIPUZKOA · DONOSTIA-SAN SEBASTIANSpain
- Altium International Sp. z o. o. · WarszawaCity levelPoland
- Azienda Ospedaliero Universitaria delle Marche · AnconaCity levelItaly
- BBD BIOPHENIX SL · San SebastianSpain
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON · ATHINAGreece
- FUNDACION CENTRO DE TECNOLOGIAS DE INTERACCION VISUAL Y COMUNICACIONES VICOMTECH · Donostia San SebastianSpain
- GDANSKI UNIWERSYTET MEDYCZNY · GdanskPoland
- KING'S COLLEGE LONDON · LondonUnited Kingdom
- KLINIKUM DER UNIVERSITAET REGENSBURG · RegensburgGermany
- LINKOPINGS UNIVERSITET · LinkopingSweden
- NORGENOTECH AS · OSLONorway
- SERVICIO MADRILENO DE SALUD · MADRIDSpain
- TECHNISCHE HOCHSCHULE DEGGENDORF · DeggendorfGermany
- TECHNISCHE UNIVERSITEIT DELFT · DelftNetherlands
- UNIVERSIDAD COMPLUTENSE DE MADRID · MadridSpain
- UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA · LeioaSpain
- UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA · RomaItaly
- UNIVERSITA POLITECNICA DELLE MARCHE · AnconaItaly
- UNIVERSITAET REGENSBURG · RegensburgGermany
Links
Data: CORDIS, © European Union